Alector (ALEC) Initiates Phase I Alzheimer's Study On AL003
Zacks Investment Research | Apr 02, 2019 09:58PM ET
Alector, Inc. (NASDAQ:ALEC) announced the initiation of the phase I INTERCEPT study on AL003 for the treatment of Alzheimer’s disease. The randomized, double-blind, placebo-controlled, dose escalation study will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of AL003 in healthy volunteers and patients with Alzheimer’s disease.
AL003 is the company's second product candidate being developed for the treatment of patients with Alzheimer's disease in collaboration with AbbVie (NYSE:ABBV) . In November, Alector initiated a phase I INVOKE study to evaluate AL002 for the treatment of Alzheimer’s disease.
Alector is focused on identifying and functionally repairing genetic mutations that cause dysfunction of the brain immune system, leading to neurodegeneration. AL003 targets SIGLEC 3, which is an inhibitory receptor expressed primarily on cells of myeloid lineage, including microglia, which constitute the brain’s immune system.
Shares of the company were up almost 7% on the announcement of the news. Alector’s stock price has increased 18.2% in the past year against the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.